40
Participants
Start Date
February 5, 2018
Primary Completion Date
December 30, 2019
Study Completion Date
April 30, 2020
Sugammadex Injection [Bridion]
The study participants will receive 10 ml syringe containing Sugammadex (2mg/kg) in the first phase followed by Placebo 10 ml syringe containing of 0.9% of normal saline in the second phase.
Placebo
The study participants will receive Placebo 10 ml syringe containing of 0.9% of normal saline in the first phase followed by 10 ml syringe containing Sugammadex (2mg/kg) in the second phase.
TWH/UHN, Toronto
Merck Sharp & Dohme LLC
INDUSTRY
University Health Network, Toronto
OTHER